This Jeanatope market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to factors such as regulatory approvals, government healthcare policies, emerging public health challenges, an aging population, and the rising prevalence of chronic diseases.
Growth during the market's forecast period will be driven by the increasing demand for diagnostic imaging, rising disposable incomes in emerging markets, the growing prevalence of hypoalbuminemia, advancements in healthcare infrastructure, and greater awareness and education. Key trends in the forecast period include improvements in plasma collection, technological innovations in healthcare, government initiatives, advances in medical technologies, and heightened consumer health awareness.
The increasing prevalence of chronic diseases is expected to drive the growth of the jeanatope market in the future. Chronic diseases are long-term health conditions that persist for three months or longer and often require continuous management. These include conditions such as diabetes, heart disease, and cancer. The rise in chronic diseases is attributed to aging populations, lifestyle changes, and the growing prevalence of risk factors such as obesity and physical inactivity. Jeanatope (iodinated I-125 albumin) injection is used in diagnostics to measure plasma volume and blood circulation, which aids in evaluating chronic diseases such as cardiovascular or renal disorders. For example, in June 2024, the Australian Institute of Health and Welfare reported that in 2022, around 15.4 million Australians (61% of the population) were living with at least one chronic condition. This prevalence varied by age, from 28% among individuals aged 0-14 to 94% among those aged 85 and over. Chronic conditions were responsible for 171,500 deaths in 2022, accounting for 90% of all deaths. The age-standardized death rate for chronic conditions was approximately 490 per 100,000 people. Therefore, the increasing burden of chronic diseases is expected to drive the growth of the jeanatope market.
The growing aging population is also expected to accelerate the growth of the jeanatope market. Population aging refers to the rising median age of a population due to lower fertility rates and increased life expectancy. This demographic shift is driven by declining birth rates and longer life spans, resulting in a higher proportion of older individuals in the population. Jeanatope I-125 is used to measure blood volume, which can assist the aging population by diagnosing conditions related to fluid balance and cardiovascular health. For example, in January 2024, the Population Reference Bureau reported that in 2022, about 57.8 million Americans aged 65 and older made up approximately 17.3% of the total U.S. population. Additionally, in June 2024, the National Council on Aging reported that in 2022, there were about 31.9 million women, and 25.9 million men aged 65 and older, with women comprising a higher proportion of this age group. Therefore, the growing aging population is contributing to the expansion of the jeanatope market.
Rising healthcare expenditure is expected to further propel the growth of the jeanatope market. Increasing healthcare spending is driven by factors such as an aging population, chronic diseases, rising service prices, greater demand, technological advancements, higher drug costs, the impact of COVID-19, medical inflation, and income disparities. Healthcare expenditure related to Jeanatope is directed toward its use in diagnostic procedures for measuring blood and plasma volume, helping manage conditions related to cardiovascular health, renal function, and fluid imbalances. For example, in November 2024, Eurostat reported that healthcare spending in Europe rose from $1.69 trillion in 2021 to $1.75 trillion in 2022, marking a 3.6% increase. Therefore, growing healthcare expenditure will continue to drive the growth of the jeanatope market.
The key company operating in the jeanatope market is Iso-Tex Diagnostics Inc.
North America was the largest region in the jeanatope market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in jeanatope report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jeanatope market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Jeanatope is a radiopharmaceutical agent used in medical imaging and diagnostics, particularly within nuclear medicine. It assists in visualizing and evaluating the function of organs or tissues, often helping to detect abnormalities such as tumors or metabolic disorders. Administered in small, safe doses, Jeanatope enables precise imaging without causing significant side effects.
The primary patient groups for jeanatope include pediatric patients, adult patients, and high-risk individuals. Adult patients typically refer to those aged 18 or older. Jeanatope is used to address specific conditions through tailored therapeutic mechanisms, such as targeting immune or disease-specific pathways. It is applied in the treatment of hemophilia A, hemophilia B, and as a prophylactic measure in surgeries, and is available through various distribution channels including hospitals, specialty clinics, pharmacies, and online pharmacies.
The jeanatope market research report is one of a series of new reports that provides jeanatope market statistics, including the jeanatope industry's global market size, regional shares, competitors with a jeanatope market share, detailed jeanatope market segments, market trends and opportunities, and any further data you may need to thrive in the jeanatope industry. This jeanatope market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The jeanatope market consists of sales of jeanatope 1-125 (iodinated 1-125 albumin injection). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to factors such as regulatory approvals, government healthcare policies, emerging public health challenges, an aging population, and the rising prevalence of chronic diseases.
Growth during the market's forecast period will be driven by the increasing demand for diagnostic imaging, rising disposable incomes in emerging markets, the growing prevalence of hypoalbuminemia, advancements in healthcare infrastructure, and greater awareness and education. Key trends in the forecast period include improvements in plasma collection, technological innovations in healthcare, government initiatives, advances in medical technologies, and heightened consumer health awareness.
The increasing prevalence of chronic diseases is expected to drive the growth of the jeanatope market in the future. Chronic diseases are long-term health conditions that persist for three months or longer and often require continuous management. These include conditions such as diabetes, heart disease, and cancer. The rise in chronic diseases is attributed to aging populations, lifestyle changes, and the growing prevalence of risk factors such as obesity and physical inactivity. Jeanatope (iodinated I-125 albumin) injection is used in diagnostics to measure plasma volume and blood circulation, which aids in evaluating chronic diseases such as cardiovascular or renal disorders. For example, in June 2024, the Australian Institute of Health and Welfare reported that in 2022, around 15.4 million Australians (61% of the population) were living with at least one chronic condition. This prevalence varied by age, from 28% among individuals aged 0-14 to 94% among those aged 85 and over. Chronic conditions were responsible for 171,500 deaths in 2022, accounting for 90% of all deaths. The age-standardized death rate for chronic conditions was approximately 490 per 100,000 people. Therefore, the increasing burden of chronic diseases is expected to drive the growth of the jeanatope market.
The growing aging population is also expected to accelerate the growth of the jeanatope market. Population aging refers to the rising median age of a population due to lower fertility rates and increased life expectancy. This demographic shift is driven by declining birth rates and longer life spans, resulting in a higher proportion of older individuals in the population. Jeanatope I-125 is used to measure blood volume, which can assist the aging population by diagnosing conditions related to fluid balance and cardiovascular health. For example, in January 2024, the Population Reference Bureau reported that in 2022, about 57.8 million Americans aged 65 and older made up approximately 17.3% of the total U.S. population. Additionally, in June 2024, the National Council on Aging reported that in 2022, there were about 31.9 million women, and 25.9 million men aged 65 and older, with women comprising a higher proportion of this age group. Therefore, the growing aging population is contributing to the expansion of the jeanatope market.
Rising healthcare expenditure is expected to further propel the growth of the jeanatope market. Increasing healthcare spending is driven by factors such as an aging population, chronic diseases, rising service prices, greater demand, technological advancements, higher drug costs, the impact of COVID-19, medical inflation, and income disparities. Healthcare expenditure related to Jeanatope is directed toward its use in diagnostic procedures for measuring blood and plasma volume, helping manage conditions related to cardiovascular health, renal function, and fluid imbalances. For example, in November 2024, Eurostat reported that healthcare spending in Europe rose from $1.69 trillion in 2021 to $1.75 trillion in 2022, marking a 3.6% increase. Therefore, growing healthcare expenditure will continue to drive the growth of the jeanatope market.
The key company operating in the jeanatope market is Iso-Tex Diagnostics Inc.
North America was the largest region in the jeanatope market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in jeanatope report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jeanatope market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Jeanatope is a radiopharmaceutical agent used in medical imaging and diagnostics, particularly within nuclear medicine. It assists in visualizing and evaluating the function of organs or tissues, often helping to detect abnormalities such as tumors or metabolic disorders. Administered in small, safe doses, Jeanatope enables precise imaging without causing significant side effects.
The primary patient groups for jeanatope include pediatric patients, adult patients, and high-risk individuals. Adult patients typically refer to those aged 18 or older. Jeanatope is used to address specific conditions through tailored therapeutic mechanisms, such as targeting immune or disease-specific pathways. It is applied in the treatment of hemophilia A, hemophilia B, and as a prophylactic measure in surgeries, and is available through various distribution channels including hospitals, specialty clinics, pharmacies, and online pharmacies.
The jeanatope market research report is one of a series of new reports that provides jeanatope market statistics, including the jeanatope industry's global market size, regional shares, competitors with a jeanatope market share, detailed jeanatope market segments, market trends and opportunities, and any further data you may need to thrive in the jeanatope industry. This jeanatope market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The jeanatope market consists of sales of jeanatope 1-125 (iodinated 1-125 albumin injection). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Jeanatope Market Characteristics4. Jeanatope Market Trends and Strategies5. Jeanatope Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Jeanatope Pricing Analysis & Forecasts30. Global Jeanatope Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Jeanatope Market32. Recent Developments in the Jeanatope Market
3. Jeanatope Market Biologic Drug Characteristics
6. Global Jeanatope Growth Analysis and Strategic Analysis Framework
8. Jeanatope Market Segmentation
9. Global Jeanatope Epidemiology of Clinical Indications
10. Jeanatope Market Regional and Country Analysis
11. Asia-Pacific Jeanatope Market
12. China Jeanatope Market
13. India Jeanatope Market
14. Japan Jeanatope Market
15. Australia Jeanatope Market
16. South Korea Jeanatope Market
17. Western Europe Jeanatope Market
18. UK Jeanatope Market
19. Germany Jeanatope Market
20. France Jeanatope Market
21. Eastern Europe Jeanatope Market
22. North America Jeanatope Market
23. USA Jeanatope Market
24. Canada Jeanatope Market
25. South America Jeanatope Market
26. Middle East Jeanatope Market
27. Africa Jeanatope Market
28. Jeanatope Market Competitive Landscape and Company Profiles
29. Global Jeanatope Market Pipeline Analysis
33. Jeanatope Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Jeanatope Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on jeanatope market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for jeanatope? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The jeanatope market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Patient Demographics: Pediatric Patients; Adult Patients; High-Risk Groups2) by Application: Treatment of Hemophilia a; Treatment of Hemophilia B; Surgical Prophylaxis
3) by Distribution Channel: Hospitals; Specialty Clinics; Pharmacies; Online Pharmacies
Key Companies Mentioned: Iso-Tex Diagnostics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Iso-Tex Diagnostics Inc.
